论文部分内容阅读
目的探讨叶酸联合瑞巴派特治疗幽门螺杆菌阴性慢性萎缩性胃炎的临床疗效。方法选取2015年6月至2016年8月首都医科大学大兴医院收治的幽门螺杆菌阴性慢性萎缩性胃炎患者82例,将其分为两组,对照组和观察组,每组41例。对照组采用叶酸进行治疗,观察组采用叶酸联合瑞巴派特进行治疗,对两组的治疗有效率以及不良反应发生率进行对比分析。结果经过治疗后,观察组疗效优于对照组,差异具有统计学意义(P<0.05);且观察不良反应发生率少于对照组,差异具有统计学意义(P<0.05)。结论叶酸联合瑞巴派特治疗幽门螺杆菌阴性慢性萎缩性胃炎的临床疗效显著,安全性高,值得在临床上进一步推广应用。
Objective To investigate the clinical efficacy of folic acid combined with rebamipide in the treatment of Helicobacter pylori-negative chronic atrophic gastritis. Methods 82 patients with Helicobacter pylori-negative chronic atrophic gastritis who were admitted to Daxing Hospital, Capital Medical University from June 2015 to August 2016 were divided into two groups, control group and observation group, with 41 cases in each group. The control group was treated with folic acid. The observation group was treated with folic acid combined with rebamipide. The treatment efficiency and the incidence of adverse reactions in the two groups were compared. Results After treatment, the observation group was better than the control group, the difference was statistically significant (P <0.05); and the incidence of adverse reactions was less than the control group, the difference was statistically significant (P <0.05). Conclusion Folic acid combined with rebamipide treatment of Helicobacter pylori-negative chronic atrophic gastritis significant clinical effect, high safety, it is worth further clinical application.